Who are DFN-15 Active's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Subutex, Buprenorphine Hydrochloride, SCH 28444, Buprenorphine (Experimental), Buprenorphine Buccal Film [Belbuca], Use of buprenorphine with FAO > 30 OME, Buprenorphine SL, Immediate Release Sublingual Buprenorphine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dfn-15-active.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

DFN-15 Active — Competitive Intelligence Brief

DFN-15 Active (DFN-15 Active) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Partial mu-opioid receptor agonist. Area: Pain Management.

phase 3 Partial mu-opioid receptor agonist Mu-opioid receptor (μ-OR) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

DFN-15 Active (DFN-15 Active) — BioDelivery Sciences International. DFN-15 is a buprenorphine sublingual tablet formulation designed to provide rapid onset and consistent opioid receptor agonism for pain management.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DFN-15 Active TARGET	DFN-15 Active	BioDelivery Sciences International	phase 3	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Subutex, Buprenorphine Hydrochloride, SCH 28444	Subutex, Buprenorphine Hydrochloride, SCH 28444	Indivior Inc.	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Buprenorphine (Experimental)	Buprenorphine (Experimental)	University of Alabama at Birmingham	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Buprenorphine Buccal Film [Belbuca]	Buprenorphine Buccal Film [Belbuca]	Carolinas Pain Institute	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Use of buprenorphine with FAO > 30 OME	Use of buprenorphine with FAO > 30 OME	Fox Chase Cancer Center	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Buprenorphine SL	Buprenorphine SL	New York State Psychiatric Institute	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Immediate Release Sublingual Buprenorphine	Immediate Release Sublingual Buprenorphine	Royal Victoria Hospital, Canada	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Partial mu-opioid receptor agonist class)

Indivior Inc. · 3 drugs in this class
New York State Psychiatric Institute · 3 drugs in this class
Orexo AB · 2 drugs in this class
BioDelivery Sciences International · 2 drugs in this class
King's College London · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Mundipharma (China) Pharmaceutical Co. Ltd · 1 drug in this class
NYU Langone Health · 1 drug in this class
National Institute on Drug Abuse (NIDA) · 1 drug in this class
Purdue Pharma LP · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DFN-15 Active — Competitive Intelligence Brief. https://druglandscape.com/ci/dfn-15-active. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab